Nextbiomedical Co (XKRX:389650) Net Margin %: -12.83% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:389650 Nextbiomedical Co Ltd XKRX:389650
38 GF Score
Price ₩33,550.00
! 1 Warning Sign
View Full Analysis

What is Nextbiomedical Co Net Margin %?

Nextbiomedical Co XKRX:389650 +1.82% 38 Net Margin % is -12.83% as of Jun. 2026. GuruFocus rates XKRX:389650 with a GF Score™ of 38/100. The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Nextbiomedical Co ranks better than 71.08% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Nextbiomedical Co's Net Income for the three months ended in Jun. 2026 was ₩-633 Mil. Nextbiomedical Co's Revenue for the three months ended in Jun. 2026 was ₩4,936 Mil. Therefore, Nextbiomedical Co's net margin for the quarter that ended in Jun. 2026 was -12.83%.

The historical rank and industry rank for Nextbiomedical Co's Net Margin % or its related term are showing as below:

XKRX:389650' s Net Margin % Range Over the Past 10 Years
Min: -1082.74   Med: -179.57   Max: 29.97
Current: 1.31

XKRX:389650's Net Margin % is ranked better than
71.08% of 944 companies
in the Biotechnology industry
Industry Median: -78.87 vs XKRX:389650: 1.31

Nextbiomedical Co  (XKRX:389650) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Nextbiomedical Co Net Margin % Related Terms

Nextbiomedical Co Net Margin % Historical Data

* Premium members only.

The historical data trend for Nextbiomedical Co's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nextbiomedical Co Net Margin % Chart

Nextbiomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial -734.13 -205.07 -154.06 29.97 -1.89

Nextbiomedical Co Quarterly Data
Dec20 Dec21 Dec22 Mar23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -22.71 21.52 -1.31 -3.54 -12.83

XKRX:389650 vs VRTX, REGN, RVMD: Net Margin % Comparison

For the Biotechnology subindustry, Nextbiomedical Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nextbiomedical Co Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nextbiomedical Co's Net Margin % distribution charts can be found below:

* The bar in red indicates where Nextbiomedical Co's Net Margin % falls into.


XKRX:389650
38GF Score
Nextbiomedical Co Ltd XKRX:389650
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nextbiomedical Co Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Nextbiomedical Co's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-311.084/16476.803
=-1.89 %

Nextbiomedical Co's Net Margin for the quarter that ended in Jun. 2026 is calculated as

Net Margin=Net Income (Q: Jun. 2026 )/Revenue (Q: Jun. 2026 )
=-633.069/4935.531
=-12.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -12.83% mean?
Nextbiomedical Co (XKRX:389650) has a Net Margin % of -12.83% as of Jun. 2026. Net margin is the ratio of total net income to net sales. View historical data on Nextbiomedical Co and its competitors. According to the industry distribution chart, Nextbiomedical Co ranks #273 out of 944 companies in the Biotechnology industry, placing it in the top 28.9%.
Is Nextbiomedical Co's Net Margin % too high?
Nextbiomedical Co's current Net Margin % is -12.83%. Based on the distribution chart, Nextbiomedical Co ranks #273 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Nextbiomedical Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Nextbiomedical Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Nextbiomedical Co ranks #273 out of 944 companies for Net Margin %. This puts Nextbiomedical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Nextbiomedical Co and its competitors. Nextbiomedical Co's current Net Margin % is -12.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nextbiomedical Co stock overvalued right now?
Nextbiomedical Co (XKRX:389650) has a current Net Margin % of -12.83%. The current Net Margin % is -12.83%. Nextbiomedical Co's overall GF Score™ is 38/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Nextbiomedical Co (XKRX:389650), the current Net Margin % is -12.83% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nextbiomedical Co Business Description

Address Venture-ro, No. 6, 100 beongil, Yeonsu-gu, Incheon, KOR
Nextbiomedical Co Ltd is an bio-solution company. The company develops and commercializes therapeutic agents for treating diseases based on polymer and drug delivery system technology. The company has developed products that include endoscopic hemostatic agents, vascular embolic microspheres, and others.
38GF Score

Get the complete analysis for XKRX:389650

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩33,550.00
Price